Please assess the completion status of the following clinical trial:

Trial Title: Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diffuse large B-cell lymphoma (DLBCL) with activating mutations in CD79 (A or B subunits). DLBCL that arose from transformed indolent lymphoma is allowed.~* Prior treatment and relapse following anthracycline-based chemotherapy and autologous bone marrow or stem cell transplant. Patients who are not transplant eligible may be considered for the study following a single regimen of chemotherapy such as R-CHOP or R-EPOCH alone. There is no limit to prior therapy allowed.~  * Patients may be treated with localized radiation to as many as two sites of disease, so long as measurable or evaluable disease remains at untreated sites.~ * Patients may be treated with corticosteriods immediately prior to enrollment and during the course of the study treatment as long as steriod treatment is tapered to a toal daily dosage of 10mg or less of prednisone (or it's equivalent) prior to AEB071 administration~* WHO performance status of ≤2~Exclusion Criteria:~* Patients at screening who are treated with strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) that can not be discontinued.~* Impaired cardiac function or clinically significant cardiac diseases, including any of the following:~* History or presence of ventricular tachyarrhythmia~* Presence of unstable atrial fibrillation (ventricular response \> 100 bpm); Patients with stable atrial fibrillation are eligible, provided they do not meet any of the other cardiac exclusion criteria.~* Angina pectoris or acute myocardial infarction ≤ 3 months prior to starting study drug~* Other clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen)~* Patients with another malignancy that was treated within the last three years with the exceptions of localized basal cell carcinoma and cervical carcinoma.~* Patients with impairment of GI function or GI disease that could interfere with the absorption of AEB071.~* Patients with a known history of Human Immunodeficiency Virus (HIV)~  * HIV testing is not required as part of this study~* Patients with a known history of active hepatitis B or C infection unless they are on antiviral therapy~  * The determination of active hepatitis status should be as per standard of care at each site~ * Hepatitis B and C testing is not required as part of this study~Time since the last prior therapy for treatment of underlying malignancy\*\*:~* Cytotoxic chemotherapy: ≤ than the duration of the most recent cycle of the previous regimen (with a minimum of 2 weeks for all)~* Biologic therapy (e.g., antibodies): ≤ 4 weeks~* ≤ 5 x t1/2 of a small molecule therapeutic, not otherwise defined above~  \*\*Patients must have recovered or stabilized from all toxicities related to their previous treatment except for alopecia~* Patients with any history of significant coagulopathy or a medical condition requiring long term systemic anticoagulation that would interfere with biopsies.~* Patients having undergone major surgery less than 4 weeks prior to enrollment or that have not fully recovered from prior surgery.~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AEB071 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).